Arvinas, Inc. insider trading
Every open-market purchase and sale by Arvinas, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Arvinas, Inc.’s insiders pay?
From April 1, 2019 to May 22, 2026, 17 insiders reported 11 open-market purchases and 56 sales not made under a pre-set plan in Arvinas, Inc. Twelve months after each purchase was reported, the shares were +54.1% against the S&P 500 on average (median +38.2%), over 10 purchases with a full year of prices; 60% beat the index. After sales, the shares moved −18.0% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 2, 2019 into $54,455 by November 2, 2026, +25.1% a year. It held shares 49% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $23,179 (+11.8% a year), and held throughout $29,514 (+15.4%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Shannon Timothy M | Director | 4 | +75.7% (4) | 100% | 4 | −32.6% (4) | September 27, 2021 |
| Houston John G | President and CEO | 0 | — | — | 7 | −28.8% (6) | March 2, 2026 |
| Taylor Ian | President, R&D | 1 | +140.4% (1) | 100% | 6 | −28.8% (6) | February 25, 2025 |
| Cacace Angela M | Chief Scientific Officer | 0 | — | — | 5 | −27.4% (2) | May 13, 2026 |
| Cassidy Sean A | Chief Financial Officer | 0 | — | — | 5 | −26.7% (5) | February 27, 2024 |
| Loomis David K | VP, Chief Accounting Officer | 0 | — | — | 5 | −54.3% (2) | May 13, 2026 |
| Ratcliffe Liam | Director | 2 | −33.4% (2) | 0% | 3 | −29.6% (3) | December 16, 2021 |
| Berkowitz Noah | Chief Medical Officer | 0 | — | — | 4 | −2.9% (1) | May 13, 2026 |
| Peck Ronald | Chief Medical Officer | 0 | — | — | 4 | +1.6% (4) | February 27, 2024 |
| Teel Randy | President and CEO | 0 | — | — | 4 | — | May 22, 2026 |
| Margus Bradley Albert | Director | 0 | — | — | 3 | −25.1% (3) | August 27, 2021 |
| Morrison Briggs | Director | 3 | −14.7% (2) | 0% | 0 | — | March 9, 2026 |
| Saik Andrew | Chief Financial Officer | 0 | — | — | 3 | −18.8% (1) | May 13, 2026 |
| 5am Co-Investors III, L.P. | 10% owner | 0 | — | — | 1 | +53.9% (1) | June 11, 2019 |
| Diekman John D | 10% owner | 0 | — | — | 1 | +134.8% (1) | April 1, 2019 |
| Kennedy Edward Moore JR. | Director | 1 | +193.6% (1) | 100% | 0 | — | November 12, 2020 |
| Schwab Andrew J. | 10% owner | 0 | — | — | 1 | +44.3% (1) | July 1, 2019 |
When several insiders traded Arvinas, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Arvinas, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −14.7% against the index. After 8 selling crowds, −36.8%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| February 27, 2026 | 5 selling | −42.9% | −43.6% | not yet |
| February 28, 2025 | 4 selling | −58.8% | −65.5% | −40.4% |
| February 29, 2024 | 4 selling | −33.1% | −54.0% | −79.1% |
| March 31, 2023 | 3 selling | −16.6% | −36.2% | +12.5% |
| March 31, 2022 | 3 selling | −21.5% | −13.6% | −50.2% |
| September 30, 2021 | 3 selling | −14.2% | −24.0% | −30.4% |
| March 31, 2021 | 3 selling | +8.1% | +14.6% | −20.6% |
| December 31, 2020 | 2 buying | −30.4% | −22.7% | −32.0% |
| March 31, 2020 | 4 selling | −36.9% | −71.7% | +7.8% |
| April 30, 2019 | 2 buying | +24.2% | −6.7% | +157.1% |